Dec 10, 2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Nov 01, 2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Oct 31, 2017
Novartis submits application to FDA for Kymriah(TM) (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Oct 18, 2017
FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
Sep 12, 2017
Companies to Watch as Biotech Makes a Comeback in 2017
Aug 30, 2017
FDA approval brings first gene therapy to the United States
Aug 30, 2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Aug 30, 2017
FDA Approves Personalized Cellular Therapy for Advanced Leukemia Developed by University of Pennsylvania and Children's Hospital of Philadelphia
Aug 30, 2017
Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Aug 30, 2017
First FDA-Approved Cell Therapy for Leukemia Utilizes Thermo Fisher Scientific's CTS Dynabeads Technology
Jul 25, 2017
Cryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia
Jun 23, 2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
Jun 07, 2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL